NEW YORK (GenomeWeb News) — The UK's Wellcome Trust will use GenoLogics' lab and data management solution in its next-generation sequencing and disease research programs, the company said today.
The Wellcome Trust Centre for Human Genetics will use the company's Geneus platform in its studies seeking the genetic basis of multi-factorial diseases such as diabetes, heart disease, multiple sclerosis, hypertension, and psychiatric disorders.
WTCHG chose the software "because of its flexibility to automate data capture from a wide range of genomics instruments and applications, while allowing us to more efficiently track samples and QC results across numerous projects," WTCHG Head of Genomics Ioannis Ragoussis said in a statement.
Ragoussis also said that the "primary consideration" in using the Geneus platform was its capability to "fully integrate our next-generation sequencing instruments from Illumina and Roche, and automatically pipeline data for downstream analysis."
The Genomics Group also provides services for other University of Oxford groups in areas of interest, such as microarray, high-throughput quantitative gene expression, high-throughput genotyping, and other specialties.